Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis

BACKGROUND: Thalidomide is an immunomodulatory and anti-angiogenic drug that has shown promise in patients with myeloma. Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Wen-Wen, Zhao, Qing-Chun, Song, De-Hai, Zhang, Jin-Jie, Ding, Zhao-Xing, Li, Bao-Yuan, Wei, Chuan-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799577/
https://www.ncbi.nlm.nih.gov/pubmed/26831235
http://dx.doi.org/10.4103/0366-6999.174497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799577/
https://www.ncbi.nlm.nih.gov/pubmed/26831235
http://dx.doi.org/10.4103/0366-6999.174497

Ejemplares similares